Back to discover
Disease

Endocrine System Diseases

Late-stage therapeutic developmentEmerging researchRising momentum
MeSHEndocrine System Diseases
3
Publications
17
Clinical trials
2
Related conditions
12
Associated genes
1
Related proteins
2021
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 6 clinical trials with recent milestones (3 completed or reporting results).
Clinical Milestones6View
Results posted 2
Recently completed 4
Activity timeline6

Clinical trials

14 sponsors · 0 new · 1 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
17
All trials
4
Active
10
Late-stage
6
Completed
Late-stage studies

A Multicenter, Extension Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

Phase 2/3 · Recruiting · Sling Therapeutics, Inc.

A Phase 2b, Randomized, Double-Mask, Placebo-Controlled, Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

Phase 2/3 · Active, not recruiting · Sling Therapeutics, Inc.

A Multi-center, Randomized, Open-label, Active-controlled, Phase IV Clinical Trial to Evaluate the Efficacy and Safety of EzetimiBe/Rosuvastatin Diabetic Dislipidemia With Hypertriglyceridaemia

Phase 4 · Completed · Seoul National University Hospital

Evolution Of Growth Rate In Children Suffering From A Disease Associated With Growth Retardation and Treated By Genotonorm. A Pilot Study.

Phase 3 · Completed · Pfizer

PaTHway CHINA TRIAL: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial, With an Open-Label Extension, Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Subcutaneously Daily in Adults With Hypoparathyroidism

Phase 3 · Completed · Visen Pharmaceuticals (Shanghai) Co., Ltd.

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study With an Open-Label Extension Assessing the Efficacy, Safety, and Pharmacokinetics/Pharmacodynamics of Tirzepatide in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, or Basal Insulin, or Both

Phase 3 · Completed · Eli Lilly and Company
Recently completed

A Multicenter, Open-Label, Extension Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency

Phase 3 · Completed · Ascendis Pharma Endocrinology Division A/S

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study With an Open-Label Extension Assessing the Efficacy, Safety, and Pharmacokinetics/Pharmacodynamics of Tirzepatide in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, or Basal Insulin, or Both

Phase 3 · Completed · Eli Lilly and Company

PaTHway CHINA TRIAL: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial, With an Open-Label Extension, Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Subcutaneously Daily in Adults With Hypoparathyroidism

Phase 3 · Completed · Visen Pharmaceuticals (Shanghai) Co., Ltd.

A Multi-center, Randomized, Open-label, Active-controlled, Phase IV Clinical Trial to Evaluate the Efficacy and Safety of EzetimiBe/Rosuvastatin Diabetic Dislipidemia With Hypertriglyceridaemia

Phase 4 · Completed · Seoul National University Hospital

Evolution Of Growth Rate In Children Suffering From A Disease Associated With Growth Retardation and Treated By Genotonorm. A Pilot Study.

Phase 3 · Completed · Pfizer

Comparison of Micro-dose Human Chorionic Gonadotropin (hCG) With HMG in PCOs Patients With Previous Clomiphene Citrate (CC)-Resistant Anovulation

Phase 1/2 · Completed · Royan Institute

Research activity

3 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20082021
Major themes1
  • Mice, Knockout1
Leading journals2
  • Endocrine reviews2
  • Environmental health and preventive medicine1
Leading researchers8
  • Behlen JC1
  • Bouillon R1
  • Bourguignon JP1
  • Carmeliet G1
  • Chen J1
  • Demay M1
  • Diamanti-Kandarakis E1
  • Giudice LC1
Affiliations (unnormalised)3
  • Katholieke Universiteit Leuven1
  • Laiko Hospital1
  • Texas A&M University1

Associated genes

12 matches

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

MRI10.34RHOH0.33CACHD10.31UBR40.30SLC4A40.29MAL20.29C1QL20.28FAXDC20.28RASEF0.28CFAP740.28HMCN20.24BIN30.24

Disease biology

1 match

Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.

Interleukin-8via CXCL80.19

Related conditions

2 matches

Diseases frequently studied alongside this one. Number shows shared papers.

Disease Models, Animal3Cardiovascular Diseases2

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Pathological processes of the ENDOCRINE GLANDS, and diseases resulting from abnormal level of available HORMONES.

Identifiers
MeSHEndocrine System Diseases
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.